Trial Profile
A Phase I, Randomised, Double Blind, Placebo Controlled, 3-part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Inhaled Doses of RPL554 Administered by Nebuliser to Healthy Male Subjects and Stable COPD Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2016
Price :
$35
*
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Verona Pharma
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 18 May 2016 Results from healthy male population presented at the 112th International Conference of the American Thoracic Society
- 12 Aug 2015 Planned number of patients changed from 120 to 112 as reported by ClinicalTrials.gov record.